Current Hypertension Reviews最新文献

{"title":"The Dose-response of Blood Pressure Variability in Stroke and Coronary Heart Disease.","authors":"Woro Riyadina, Sulistyowati Tuminah, Lely Indrawati, Nikson Sitorus, Alfons M Letelay, Tri Wurisastuti, Alifa Syamantha Putri, Ika Suswanti, Yuda Turana","doi":"10.2174/0115734021346604250214071418","DOIUrl":"https://doi.org/10.2174/0115734021346604250214071418","url":null,"abstract":"<p><strong>Background: </strong>Blood pressure variability (BPV) is a potential predictor of vascular events and triggers target organ damage.</p><p><strong>Objective: </strong>This study aimed to determine the BPV in stroke and coronary heart disease (CHD) in the Bogor Cohort Study in Indonesia.</p><p><strong>Methods: </strong>Over six years of monitoring, a prospective cohort study was conducted on 1649 respondents aged ≥ 31 years from the Bogor Non-communicable Diseases Risk Factors Cohort Study. The dependent variable was vascular events (stroke or CHD), which were new cases (incidents) that appeared during the 6-year monitoring period (2011 - 2017 and 2012-2018).</p><p><strong>Result: </strong>During the six years of monitoring, the incidence of vascular events was 12.4 percent. The dose-response of systolic and diastolic BPV in vascular events, stroke, and coronary heart disease showed an increased risk (quintiles Q2, Q3, and Q4) compared to quintile 1 (Q1). Systolic BPV of ≥12,10 mmHg and diastolic BPV of ≥ 7,31 mmHg had a risk of 2.3 and 1.7 (95% Confidence Intervals (CI)), respectively, for vascular events during the period of 6-year observation, after controlling for age, hypertension status, and lipid profile.</p><p><strong>Conclusion: </strong>BPV is an independent predictor of vascular events, stroke, and coronary heart disease. The public and clinicians must pay attention to controlling BPV as a risk factor for vascular events, stroke, and CHD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis.","authors":"Huiduo Wang, Hongxin Yang, Zhiyong Zhang, Hao Guo","doi":"10.2174/0115734021357729250214090452","DOIUrl":"https://doi.org/10.2174/0115734021357729250214090452","url":null,"abstract":"<p><strong>Background: </strong>Dihydropyridine-calcium channel blockers (DHP-CCBs) are effective first-line blood pressure-lowering agents for primary hypertension. However, data comparing the variations in efficacy and safety between different types of DHP-CCBs are scarce.</p><p><strong>Aims and objectives: </strong>This study aimed to summarize the latest evidence on the benefits and harms of seven DHP-CCBs (amlodipine, levamlodipine, felodipine, lacidipine, nitrendipine, nifedipine, and benidipine).</p><p><strong>Methods: </strong>A meta-analysis of DHP-CCBs was carried out to explore differences in efficacy and safety. We searched PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data, and VIP databases from inception to September, 2023, for randomized controlled trials (RCTs) comparing DHP-CCBs. The main outcomes were blood pressure lowering and adverse events (AEs) during treatment.</p><p><strong>Results: </strong>We included 181 RCTs (21,383 patients) in this analysis. In terms of efficacy, levamlodipine ranked highest in reducing office blood pressure (surface under the cumulative ranking systolic blood pressure = 80.81%, diastolic blood pressure [DBP] = 82.42%) and 24-h ambulatory DBP (98.07%). Felodipine had the highest probability of reducing 24-h ambulatory blood pressure (80.65%). Regarding safety, levamlodipine had the least impact on heart rate (85.71%). In terms of AEs, benidipine had the highest rate for cardiovascular (86.58%) and digestive system (93.57%) AEs. Nifedipine and amlodipine had the highest rates of central (80.65%) and peripheral nervous system (83.28%) AEs, respectively. Levamlodipine exhibited significantly lower rates of total AEs (1.24%), central nervous system AEs (1.28%), and cardiovascular system AEs (3.62%) than the other interventions.</p><p><strong>Conclusion: </strong>In the office setting, levamlodipine may be the best treatment for primary hypertension, and lacidipine shows good safety.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Combined Effect of Smoking and Obesity on Hypertension: Implications for Clinical Management.","authors":"Dimitrios Aragiannis, Alexandros Kasiakogias, Panagiotis Iliakis, Marios Sagris, Fotios Panagiotis Tatakis, Eleni Manta, Ioannis Andrikou, Dimitrios Konstantinidis, Konstantinos Tsioufis","doi":"10.2174/0115734021351026250126165154","DOIUrl":"https://doi.org/10.2174/0115734021351026250126165154","url":null,"abstract":"<p><p>A significant proportion of hypertensive patients are both smokers and obese. Several pathophysiological mechanisms are involved in the combined effect of smoking and obesity on hypertension onset and maintenance. These include increased sympathetic nervous system activity, endothelial dysfunction, inflammation, oxidative stress, and insulin resistance. The presence of these major cardiovascular risk factors may lead to difficult-to-control hypertension as well as substantially increase the risk for an adverse cardiovascular outcome. It is, therefore, imperative that healthcare providers embrace a comprehensive, multifaceted approach in the management of obese hypertensive patients with smoking habits. This review delves into the complex interplay of these risk factors, providing a comprehensive overview of the current literature to aid the deployment of effective clinical management strategies toward reducing the risk profile of affected individuals.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Accuracy of 24-Hour Ambulatory Blood Pressure Monitoring Versus Clinic Blood Pressure for Cardiovascular and All-Cause Mortality: A Systematic Review and Meta-Analysis.","authors":"Hamidreza Soleimani, Negin Sadat Hosseini Mohammadi, Sara Montazeri Namin, Amir Nasrollahizadeh, Tara Azardar, Kimia Najafi, Mehmet Cilingiroglu, Mushabbar Syed, Mani K Askari, Rahul Gupta, Wilbert S Aronow, Kaveh Hosseini","doi":"10.2174/0115734021337639250203175636","DOIUrl":"https://doi.org/10.2174/0115734021337639250203175636","url":null,"abstract":"<p><strong>Background: </strong>According to current clinical practice guidelines, ambulatory blood pressure measurement (ABPM) is recommended to confirm diagnoses of hypertension. It remains unclear as to which method is superior in predicting mortality outcomes.</p><p><strong>Methods: </strong>Prospective observational studies, comparing ABPM with clinical blood pressure measurements (CBPM), were included with outcomes of the study being all-cause and cardiovascular mortality.</p><p><strong>Results: </strong>Nine studies with a total of 23,140 participants were included. Each 10-mmHg increase in 24-hour mean systolic blood pressure (SBP) was linked to a higher risk of all-cause mortality (HR: 1.13, 95% CI: 1.09-1.18), while clinic blood pressure measurement (CBPM) was not a significant predictor (HR: 1.02, 95% CI: 0.90-1.13). Nighttime SBP increases of 10 mmHg were associated with a higher all-cause mortality risk than daytime SBP (HR: 1.16, 95% CI: 1.11-1.21 versus HR: 1.08, 95% CI: 1.05-1.12). For cardiovascular mortality, a 10 mmHg increase in SBP yielded an HR of 1.21 (95% CI: 1.16-1.27) for 24-hour ABPM compared to 1.08 (95% CI: 1.04-1.11) for CBPM. Similarly, for a 5 mmHg increase in diastolic blood pressure (DBP), the HR was 1.14 (95% CI: 1.07-1.20) for 24-hour ABPM versus 1.04 (95% CI: 1.01-1.07) for clinical DBP, highlighting 24-hour monitoring as a stronger predictor for cardiovascular mortality.</p><p><strong>Conclusion: </strong>The findings of this study support the superiority of ABPM measurements in predicting both all-cause and cardiovascular mortality.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-Section of Hypertensive Molecular Signaling Pathways: Understanding Pathogenesis and Identifying Improved Drug Targets.","authors":"Jeyanthi Sankar, Kannan Rajendran, Ling Shing Wong, Karthikeyan Muthusamy","doi":"10.2174/0115734021342501250107052350","DOIUrl":"https://doi.org/10.2174/0115734021342501250107052350","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a chronic medical state and a major determining factor for cardiovascular and renal diseases. Both genetic and non-genetic factors contribute to hypertensive conditions among individuals. The renin-angiotensin-aldosterone system (RAAS) is a major genetic target for the anti-hypertension approach.</p><p><strong>Purpose of the study: </strong>The majority of classical antihypertensive drugs were mainly focused on the RAAS signaling pathways. Though these antihypertensive drugs control blood pressure (BP), they have mild to severe life-threatening effects. Unrevealing effective hypertensive targets for BP management is essential. The effective targets could emerge either from RAAS-dependent or RAAS-independent pathways and/or through the cross-talks among them.</p><p><strong>Results: </strong>Analyzing the physiopathological mechanisms of hypertension has the benefit of understanding the interactions between these systems which helps in better understanding of drug targets and the importance of emergence of novel therapeutics.</p><p><strong>Conclusion: </strong>This review is about the signaling pathways involved in hypertension pathogenesis and their cross-talks and it contributes to a better understanding of the etiology of hypertension.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Efficacy of Using ACEIs and ARBs in Chronotherapeutic Treatment of Hypertension: Which Drug When?","authors":"Jasmine Yadav, Naim Khan, RIna Das, Dinesh Kumar Mehta","doi":"10.2174/0115734021332079241226115916","DOIUrl":"https://doi.org/10.2174/0115734021332079241226115916","url":null,"abstract":"<p><p>Hypertension, a prevalent global health issue, poses significant risks for morbidity and mortality. The interplay between hypertension and comorbidities like diabetes and chronic kidney disease (CKD) underscores the urgency for effective management strategies. Chronotherapy, aligning medication administration with circadian rhythms, emerges as a promising approach to optimize treatment outcomes. The objective of this study is to assess the safety and efficacy of the use of ACEIs and ARBs in the chronotherapeutic treatment of hypertension. We aim to clarify the influence of circadian blood pressure patterns on the efficacy of medications and investigate the potential of chronotherapy in the management of hypertension by conducting a thorough examination of the existing literature. A literature search spanning from January 1980 to 2023 was conducted using PubMed, Scopus and Google Scholar databases. Search terms included ACE inhibitors, ARBs, chronotherapy, hypertension, and circadian rhythm of blood pressure. Studies investigating the effects of chronotherapy with ACEIs and ARBs in hypertensive patients were analyzed. Chronotherapy offers a personalized approach to hypertension management, leveraging the dynamic nature of circadian rhythms. By administering ACEIs or ARBs at night, the risk of morning blood pressure surges, associated with adverse cardiovascular events, can be mitigated. However, the optimal timing and combination of medications remain areas of ongoing research. Our review highlights the potential of chronotherapy with ACEIs and ARBs as a promising avenue for hypertension treatment. Further research is warranted to elucidate the mechanisms underlying circadian blood pressure regulation and optimize chronotherapeutic strategies. This comprehensive evaluation underscores the need for personalized treatment approaches tailored to individual circadian rhythms for improved hypertension management and reduced cardiovascular risk.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of New Symmetrical and Asymmetrical 1,4-dihydropyridine Derivatives as Potential Antihypertensive Agents: An In silico Evaluation.","authors":"Ruhani Raj, Charu Parjapati, Minakshi Garg, Anupreet Kaur","doi":"10.2174/0115734021328359241206073629","DOIUrl":"https://doi.org/10.2174/0115734021328359241206073629","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a worldwide problem that affects people of all ethnicities and social groups. Its mortality rate has been steadily increasing. However, several pharmacological compounds have been used to manage hypertension and related issues. Calcium Channel Blockers (CCBs) based on Dihydropyridine (DHP) are used as first-line therapy. It is well established that simple adjustments to an existing medicine's fundamental structure can considerably improve its efficacy.</p><p><strong>Materials and methods: </strong>The purpose of this research study was to create potential antihypertensive drugs utilizing a 1,4-DHP scaffold and analyze their binding processes with different calcium channel proteins for comparative analysis, with PDB IDs 3LV3, 1T0J, and 6DAF. This study used molecular docking and ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling to predict the binding efficacy of newly produced potential drugs, such as CCBs.</p><p><strong>Results: </strong>The binding energy of the protein with the newly created compounds ranged between -2.6 and -7.26 kcal/mol (3LV3), -7.42 to -10.36 kcal/mol (1T0J), and -6.63 to -11.98 kcal/mol (6DAF).</p><p><strong>Discussion: </strong>The predicted ADMET profiling yielded significant results, indicating that among the virtually prepared ligands, apart from the standard drugs amlodipine and nifedipine, ligand numbers 60 and 13 showed a favorable ADMET profile.</p><p><strong>Conclusion: </strong>In this study, drug development efforts focused on modifying existing hypertension medications through in silico analysis. From hundreds of synthesized ligands, 19 showed optimal docking scores. ADMET profiling of these 19 ligands revealed ligands 60 and 13 to have favorable profiles. The Swiss ADME and ADMET lab 2.0 tools confirmed these findings, highlighting their potential for further development.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.","authors":"Surbhi Gupta, Prabhat Singh, Bhupesh Sharma","doi":"10.2174/0115734021276985231204092425","DOIUrl":"10.2174/0115734021276985231204092425","url":null,"abstract":"<p><strong>Background: </strong>Declined kidney function associated with hypertension is a danger for cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD) are serious public health concerns, which highlights the urgent need for study on the risk factors for cognitive decline. Cysteinyl leukotriene (CysLT₁) receptors are concerned with regulating cognition, motivation, inflammatory processes, and neurogenesis.</p><p><strong>Objective: </strong>This research aims to examine the consequence of montelukast (specific CysLT₁ antagonist) in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental animals.</p><p><strong>Methods: </strong>2K1C tactics were made to prompt renovascular hypertension in mature male rats. Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum nitrite levels, aortic superoxide content, vascular endothelial activity, brain's oxidative stress (diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α), cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5- triphenylterazolium chloride) were also examined.</p><p><strong>Results: </strong>Montelukast in doses of 5.0 and 10.0 mg kg^-1 was used intraperitoneally as the treatment drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension- provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.</p><p><strong>Conclusion: </strong>The 2K1C tactic caused renovascular hypertension and associated VaD, which was mitigated via targeted regulation of CysLT₁ receptors by montelukast administration. Therefore, montelukast may be taken into consideration for the evaluation of its complete potential in renovascular-hypertension-induced VaD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"23-35"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Effect of COVID-19 on Pregnancy-Induced Hypertension (HTN): A Case-Control Study.","authors":"Mohadeseh Nazari Fathabad, Rasoul Raesi, Kiavash Hushmandi, Shiva Kargar, Haniyeh Safipour, Salman Daneshi","doi":"10.2174/0115734021319741240905163734","DOIUrl":"10.2174/0115734021319741240905163734","url":null,"abstract":"<p><strong>Background: </strong>Suppression of the body's immune system can cause high blood pressure. Also, many people with COVID-19 have underlying diseases, including high blood pressure.</p><p><strong>Aim: </strong>This study was conducted to investigate the effect of COVID-19 infection on blood pressure caused by pregnancy in women referred to Kashani Hospital in Jiroft City.</p><p><strong>Methods: </strong>This study was a case-control study with a census sampling method on 266 pregnant women referring to Kashani Hospital in Jiroft City in 2021-2022. Pregnant women were divided into two control groups (pregnant women without COVID-19) and intervention (pregnant women with COVID-19). SPSS software version 22 was analyzed.</p><p><strong>Results: </strong>266 pregnant women participating in the study were divided into two equal control (133) and intervention (133) groups. The average age of pregnant women was 29 ± 6.8 years. The average systolic and diastolic blood pressure in the intervention group was 112.6 and 70, and in the control group, it was 107.8 and 66.6, which was not statistically significant (P_Value>0.05). Also, the results showed that there was a difference between home blood pressure during pregnancy and there is a statistically significant relationship between the age of pregnant women (P_Value< 0.05). While there is no significant statistical relationship between gestational age and body mass index (P_Value>0.05).</p><p><strong>Conclusion: </strong>According to the results of this study, COVID-19 affects blood pressure caused by pregnancy, and gestational age is an important factor in the prevalence of high blood pressure in women with COVID-19.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"176-182"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods Study.","authors":"Ekow Mensah, Khalid Ali, Michael Okorie, Stephen Bremner, Colin McAlister, Nicky Perry, Chakravarthi Rajkumar","doi":"10.2174/0115734021299574240809114921","DOIUrl":"10.2174/0115734021299574240809114921","url":null,"abstract":"<p><strong>Introduction: </strong>There is a recognised association between white coat hypertension (WCH) and adverse cardiovascular outcomes in older adults. However, there is no consensus on the management of WCH in this group. The objective of the Hypertension in the Very Elderly Trial (HYVET-2) study was to assess the feasibility of randomising 100 patients > 75years with WCH from General Practice in the UK to treatment or usual care. The study did not randomise any patients. In this follow-up study, we sought to explore the reasons for not recruiting.</p><p><strong>Methods: </strong>Furthermore, using a mixed-methods study design, staff from 29 General Practice (GP) sites and the Clinical Research Network (CRN) in Kent, Surrey, and Sussex (KSS), UK, were sent an online questionnaire about local research facilities and infrastructure, and HYVET-2 study methodology and target population demographics.</p><p><strong>Results: </strong>Nineteen (19) individuals responded to the online questionnaires (15 primary care staff, 4 CRN staff). Moreover, using a framework approach, we identified six themes summarising challenges to HYVET-2 recruitment. These themes are established approaches of primary care towards managing WCH in older people, target patient demographics, study design complexity, patient- facing study documents, limited research resources in primary care, and identification of eligible patients using existing coding.</p><p><strong>Conclusion: </strong>Our experience showed that recruiting older people from primary care to a WCH study was not feasible. A national scoping survey amongst primary care physicians in the UK, as well as robust patient and public involvement (PPI) targeting older people with WCH, might improve recruitment in future studies addressing the management of WCH in older people.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"156-165"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}